Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Decreases By 52.7%

Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 18,500 shares, a decline of 52.7% from the September 30th total of 39,100 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 16,100 shares, the days-to-cover ratio is presently 1.1 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Akari Therapeutics in a research note on Friday. They set a “sell” rating for the company.

Akari Therapeutics Price Performance

AKTX stock traded up $0.09 during trading on Friday, hitting $2.36. 12,499 shares of the company’s stock were exchanged, compared to its average volume of 17,876. The business has a 50-day moving average price of $3.12 and a two-hundred day moving average price of $2.74. Akari Therapeutics has a 52-week low of $1.08 and a 52-week high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.